Single Use Support - Cold Chain
Pharma Focus Europe
ACROBiosystems - Survey EU
Robert S. Radie

Share

facebook-icon linkedin-icon twitter pinterest

Robert S. Radie

Robert S. Radie
Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board

Monument Therapeutics, a precision-neuroscience company advancing innovative treatments for serious central nervous system (CNS) disorders, announced two key additions to its leadership team. 

Robert S. Radie has been appointed Non-Executive Chair of the Board, and Dr. Heather Preston has joined the company’s Advisory Board.

Mr. Radie brings over 30 years of experience in the pharmaceutical and biotechnology industries, with a strong track record in psychiatric and neurological therapeutics. He previously played a key role in the commercial success of several CNS drugs at Eli Lilly and has led multiple neuroscience-focused companies, including Prestwick Pharmaceuticals and Zyla Life Sciences. He currently serves as CEO and Chair of Neuraptive Therapeutics and holds board positions at Orcosa, Rockwell Medical (Chair), and ValSource. His past board service includes Paratek Pharmaceuticals and Veloxis Inc.

These appointments reflect Monument Therapeutics' ongoing commitment to strengthening its leadership and advisory capabilities as it advances its precision neuroscience pipeline.

Related posts

Dr. Sanjay Keswani

Dr. Sanjay Keswani
Scenic Biotech Appoints Dr. Roland W. Bürli as Chief Scientific Officer to Drive Advancement of Modifier Therapies

Dr. Roland W. Bürli
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

Antoinette Paone
AEON Biopharma, Inc. Appoints John Bencich as Chief Financial Officer

John Bencich
INFORS HT || The Minitron SE
Fluidic - Better Antibody Discovery
Pharma Access - A Better Way to Build
Yokogawa - Smart Manufacturing and Beyond
Molecular Devices - CellXpress.ai®
Valsynthese - IMIDE Chemistry